Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study.

Related Articles Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study. Target Oncol. 2019 12;14(6):699-705 Authors: Legué LM, van Erning FN, Bernards N, Lemmens VEPP, de Hingh IHJT, Creemers GJ Abstract BACKGROUND: Data about the use and effectiveness of targeted therapy in metastatic small bowel adenocarcinoma (SBA) are scarce. OBJECTIVE: The aim of this population-based study was to obtain insights into the use and effectiveness of targeted therapy in patients with synchronous metastases of SBA. PATIENTS AND METHODS: Data were retrieved from the Netherlands Cancer Registry. Patients treated with palliative chemotherapy and/or…
Origen: Addition of Bevacizumab to First-Line Palliative Chemotherapy in Patients with Metastatic Small Bowel Adenocarcinoma: A Population-Based Study. – PubMed